Revelation Biosciences Overview
Latest ROE for Revelation Biosciences: -147705.72% — see history and peer comparisons.
Get informed when a big investor buys or sells
+ Follow-147705.72%
Return on Equity measures how efficiently a company uses shareholders' equity to generate profits. A higher ROE indicates better profitability relative to equity.
Revelation Biosciences (REVB) currently reports a ROE of -147705.72%. That is below the sector sector average of 11.73%. Use the charts on this page to explore Revelation Biosciences's ROE history and peer comparisons.
Revelation Biosciences's ROE of -147705.72% is lower than the its sector sector average of 11.73%. That is roughly 1258899.8% below the sector mean. A reading lower peers can reflect different growth expectations, capital structure, or profitability — so it is worth checking the peer comparison chart before drawing conclusions.
There is no universal 'good' ROE, but Revelation Biosciences's current -147705.72% should be judged against industry norms (sector average: 11.73%) and against REVB's own history. Strong, stable readings often indicate durable competitive advantage; volatile or declining ones deserve a closer look at margins and capital efficiency.
Start with the current ROE of -147705.72%, then check the historical chart for trend and the peer comparison chart for relative positioning. The sector average is 11.73%. From there, open related valuation or income-statement pages for Revelation Biosciences, and consider following REVB for alerts when major investors trade the stock.
